Systemic Antimicrobial Therapy in Osteomyelitis

ABSTRACT

Appropriately designed antibiotic regimens are critical to the management of all stages of osteomyelitis, although goals of therapy may vary in different stages of infection. The most important consideration for antibiotic selection is spectrum of action. Route of administration by intravenous or oral route is less important than drug levels that are achievable at the site of infection. Outpatient parenteral therapy and use of oral agents has simplified delivery of long-term treatment regimens. There are few high-quality studies that compare specific treatment regimens or durations of therapy, and recommendations for drugs and duration of antibiotic therapy are based on expert opinion, case series, and extrapolations from animal models. Intravenous β-lactams are the treatment of choice for methicillin-susceptible Staphylococcus aureus, but there are also oral options available. Vancomycin has been the treatment of choice for methicillin-resistant Staphylococcus aureus osteomyelitis, but there are several newer parenteral and oral agents for treatment of methicillin-resistant Staphylococcus aureus including linezolid and daptomycin. Rifampin combined with other staphylococcal agents may increase cure rates, especially for device-associated infections. Oral fluoroquinolones and parenteral β-lactam agents can be used for treatment of gram-negative osteomyelitis, but increasing resistance has complicated management of these infections.

KEYWORDS

Osteomyelitis - Staphylococcus aureus osteomyelitis - methicillin-resistant Staphylococcus aureus - outpatient parenteral antibiotic therapy - fluoroquinolones

REFERENCES

• 1 Lew D P, Waldvogel F A. Osteomyelitis.  Lancet. 2004;  364 369-379
• 2 Mader J T, Norden C, Nelson J D, Calandra G B. Evaluation of new antiinfective drugs for the treatment of osteomyelitis in adults.  Clin Infect Dis. 1992;  15 S155-S161
• 3 Lazzarini L, Lipsky B A, Mader J T. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trails?.  Int J Infect Dis. 2005;  9 127-138
• 4 Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzoit F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections.  Lancet Infect Dis. 2001;  1 175-188
• 5 Lazzarini L, de Lalla F, Mader J T. Long bone osteomyelitis.  Curr Infect Dis Rep. 2002;  4 439-445
• 6 Rybak M J. Pharmacodynamics: relation to antimicrobial resistance.  Am J Med. 2006;  119 S37-S44
• 7 Senneville E, Legout L, Valette M et al.. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study.  Clin Ther. 2006;  28 1155-1163
• 8 Mader J T, Cantrell J S, Calhoun J. Oral ciprofloxacin therapy compared with standard parenteral therapy for chronic osteomyelitis in adults.  J Bone Joint Surg Am. 1990;  72 104-110
• 9 Kaplan S L, Mason E O, Feigen R D. Clindamycin versus nafcillin or methicillin in the treatment of S. aureus osteomyelitis in children.  South Med J. 1982;  75 138-142
• 10 Tice A D, Hoaglund P A, Shoultz D A. Risk factors and treatment outcomes in osteomyelitis.  J Antimicrob Chemother. 2003;  51 1261-1268
• 11 Cremieux A C, Carbon C. Experimental models of bone and prosthetic joint infections.  Clin Infect Dis. 1997;  25 1295-1302
• 12 Lazzarini L, Overgaard K A, Conti E, Shirtliff M E. Experimental osteomyelitis: what have we learned from animal studies about the systemic treatment of osteomyelitis?.  J Chemother. 2006;  18 451-460
• 13 Salgado C J, Jamali A A, Mardini S, Buchanan K, Veit B. A model for chronic osteomyelitis using Staphylococcus aureus in goats.  Clin Orthop Relat Res. 2005;  436 246-250
• 14 Lipsky B A, Berendt A R, Deery G H for the Infectious Diseases Society of America et al. IDSA guidelines: diagnosis and treatment of diabetic foot infections.  Clin Infect Dis. 2004;  39 885-910
• 15 Esposito S, Leone S, Noviello S. Outpatient parenteral antibiotic therapy for bone and joint infections: an Italian multicenter study.  J Chemother. 2007;  19 417-422
• 16 Carragee E J, Kim D, van der Vlugt T, Vittum D. The clinical use of erythrocyte sedimentation rate in pyogenic vertebral osteomyelitis.  Spine. 1997;  22 2089-2093
• 17 Roine I, Faingezicht I, Arguedas A, Herrera J F, Rodríguez F. Serial serum C-reactive protein to monitor recovery from acute hematogenous osteomyelitis in children.  Pediatr Infect Dis J. 1995;  14 40-44
• 18 Bocchini C E, Hulten K G, Mason Jr E O et al.. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children.  Pediatrics. 2006;  117 433-440
• 19 Klevens R M, Morrison M A, Nadle J et al.. Invasive methicillin-resistant Staphylococcus aureus infections in the United States.  JAMA. 2007;  298 1763-1771
• 20 Guglielmo B J, Luber A D, Paletta Jr D, Jacobs R A. Ceftriaxone therapy for staphylococcal osteomyelitis: a review.  Clin Infect Dis. 2000;  30 205-207
• 21 Peltola H, Unkila-Kallio L, Kallio M J. Simplified treatment of acute staphylococcal osteomyelitis of childhood. The Finnish Study Group.  Pediatrics. 1997;  99 846-850
• 22 Jaberi F M, Shahcheraghi G H, Ahadzadeh M. Short-term intravenous antibiotic treatment of acute hematogenous bone and joint infection in children: a prospective randomized trial.  J Pediatr Orthop. 2002;  22 317-320
• 23 Norden C W, Fierer J, Bryant R. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin.  Rev Infect Dis. 1983;  5 S495-S501
• 24 Shorr A F. Epidemiology of staphylococcal resistance.  Clin Infect Dis. 2007;  45 S171-S176
• 25 Small P M, Chambers H F. Vancomycin for S. aureus endocarditis in intravenous drug users.  Antimicrob Agents Chemother. 1990;  34 1227-1231
• 26 Kollef M H. Limitations of vancomycin in the management of resistant staphylococcal infections.  Clin Infect Dis. 2007;  45 S191-S195
• 27 Hidayat L K, Hsu D I, Quist R et al.. High-dose vancomycin therapy for methicillin-resistant S. aureus infections: efficacy and toxicity.  Arch Intern Med. 2006;  166 2138-2144
• 28 Norden C W, Shinners E, Niederriter K. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus.  J Infect Dis. 1986;  153 956-959
• 29 Rodriguez W, Ross S, Khan W, McKay D, Moskowitz P. Clindamycin in the treatment of osteomyelitis in children.  Am J Dis Child. 1977;  131 1088-1093
• 30 Siberry G K, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant S. aureus expressing inducible clindamycin resistance in vitro.  Clin Infect Dis. 2003;  37 1257-1260
• 31 Saengnipanthkul S, Pongvivat T, Mahaisavariya B, Laupattarakasem W. Co-trimoxazole in the treatment of chronic osteomyelitis.  J Med Assoc Thai. 1988;  71 186-191
• 32 Markowitz N, Quinn E L, Saravolatz L D. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of S. aureus infection.  Ann Intern Med. 1992;  117 390-398
• 33 Atkins B, Gottlieb T. Fusidic acid in bone and joint infections.  Int J Antimicrob Agents. 1999;  12 S79-S93
• 34 Rissing J P. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones.  Clin Infect Dis. 1997;  25 1327-1333
• 35 Melhus A. Fluoroquinolones and tendon disorders.  Expert Opin Drug Saf. 2005;  4 299-309
• 36 Metzler K, Hansen G M, Hedlin P et al.. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant S. aureus. .  Int J Antimicrob Agents. 2004;  24 161-167
• 37 Drancourt M, Stein A, Argenson J N et al.. Oral rifampicin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants.  Antimicrob Agents Chemother. 1993;  37 1214-1218
• 38 Ruhe J J, Monson T, Bradsher R W, Menon A. Use of long-acting tetracyclines for methicillin-resistant S. aureus infections: case series and review of the literature.  Clin Infect Dis. 2005;  40 1429-1434
• 39 Lovering A M, Zhang J, Bannister G C et al.. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement.  J Antimicrob Chemother. 2002;  50 73-77
• 40 Rayner C R, Baddour L M, Birmingham M C et al.. Linezolid in the treatment of osteomyelitis: results of compassionate use experience.  Infection. 2004;  32 8-14
• 41 Falagas M E, Siempos I I, Papagelopoulos P J, Vardakas K Z. Linezolid for the treatment of adults with bone and joint infections.  Int J Antimicrob Agents. 2007;  29 233-239
• 42 Rao N, Ziran B H, Wagener M M, Santa E R, Yu V L. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections.  Clin Infect Dis. 2004;  38 1058-1064
• 43 Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval.  Pharmacology. 2007;  81 79-91
• 44 Lamp K C, Friedrich L V, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis.  Am J Med. 2007;  120 S13-S20
• 45 Yin L Y, Lazzarini L, Li F, Stevens C M, Calhoun J H. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model.  J Antimicrob Chemother. 2005;  55 995-1002
• 46 Zimmerli W, Widmer A F, Blatter M, Frei R, Ochsner P E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.  JAMA. 1998;  20 1537-1541
• 47 Mulleman D, Philippe P, Senneville E et al.. Streptococcal and enterococcal spondylodiscitis (vertebral osteomyelitis). High incidence of infective endocarditis in 50 cases.  J Rheumatol. 2006;  33 91-97
• 48 Rice L B. Antimicrobial resistance in gram-positive bacteria.  Am J Infect Control. 2006;  34 S11-S19
• 49 Graham A C, Mercier R C, Achusim L E, Pai M P. Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis.  Ann Pharmacother. 2004;  38 936-941
• 50 Leibovitz E. The use of fluoroquinolones in children.  Curr Opin Pediatr. 2006;  18 64-70
• 51 Bodi M, Garnacho J. Pseudomonas aeruginosa: combined treatment vs. monotherapy.  Med Intensiva. 2007;  31 83-87
• 52 Tascini C, Gemignani G, Palumbo F et al.. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant P. aeruginosa diabetic foot infections with or without osteomyelitis.  J Chemother. 2006;  18 648-651
• 53 American Thoracic Society, CDC, and Infectious Diseases Society of America . Treatment of tuberculosis.  Am J Respir Crit Care Med. 2003;  167 603-662
• 54 American Thoracic Society and Infectious Diseases Society of America . ATS/IDSA statement: diagnosis, prevention and treatment of nontuberculous mycobacterial diseases.  Am J Respir Crit Care Med. 2007;  175 367-416
• 55 Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis.  N Engl J Med. 2005;  352 2325-2336
• 56 Robinson J L, Vaudry W L, Dobrovolsky W. Actinomycosis presenting as osteomyelitis in the pediatric population.  Pediatr Infect Dis J. 2005;  24 365-369